Table 2.
Estimated annualized change in log BMP concentrations in LRRK2 cohorts.
| BMP isoform | Disease status | Estimated log change over 12 months (95% CI) | P value |
|---|---|---|---|
| a LRRK2 G2019S+ sub-cohorts. | |||
| Total di-18:1-BMP | PD |
0.0677 (0.0020, 0.1335) |
0.0435 |
| NMC |
0.0529 (−0.0039, 0.1096) |
0.0677 | |
| PD vs NMC |
0.0149 (−0.0720, 0.1017) |
0.7363 | |
| Total di-22:6-BMP | PD |
0.0144 (−0.0379, 0.0668) |
0.5882 |
| NMC |
0.0312 (−0.0139, 0.0764) |
0.1748 | |
| PD vs NMC |
−0.0168 (−0.0860, 0.0524) |
0.6332 | |
| 2,2’ di-22:6-BMP | PD |
0.0127 (−0.0471, 0.0725) |
0.6768 |
| NMC |
0.0203 (−0.0313, 0.0718) |
0.4404 | |
| PD vs NMC |
−0.0076 (−0.0865, 0.0714) |
0.8505 | |
| b LRRK2 R1441G+ sub-cohorts. | |||
|---|---|---|---|
| Total di-18:1-BMP | PD |
0.1046 (−0.0763, 0.2855) |
0.2503 |
| NMC |
0.1901 (0.0074, 0.3727) |
0.0417 | |
| PD vs NMC |
−0.0854 (−0.3427, 0.1718) |
0.5073 | |
| Total di-22:6-BMP | PD |
0.0903 (−0.0235, 0.2041) |
0.1172 |
| NMC |
0.1344 (0.0189, 0.2498) |
0.0235 | |
| PD vs NMC |
−0.0441 (−0.2063, 0.1181) |
0.5869 | |
| 2,2’ di-22:6-BMP | PD |
0.1172 (−0.0159, 0.2502) |
0.0829 |
| NMC |
0.1433 (0.0085, 0.2781) |
0.0377 | |
| PD vs NMC |
−0.0262 (−0.2157, 0.1633) |
0.7824 | |
Linear Mixed Models (LMM) were used to estimate the annualized change in log BMP concentrations with fixed effects of disease status and time and interaction between them after adjusting for age and sex. Significant P values are shown in bolded font.
PD Parkinson’s disease, NMC non-manifesting carriers, BMP bis(monoacylglycerol)phosphate.